NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
0.740
+0.029 (4.04%)
Jan 22, 2025, 10:43 AM EST - Market open
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for NBY stock has a target of 0.85, which predicts an increase of 14.88% from the current stock price of 0.74.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for NBY is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $8 → $0.85 | Strong Buy | Maintains | $8 → $0.85 | +14.88% | Nov 11, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5,206 → $4,900 | Strong Buy | Maintains | $5,206 → $4,900 | +662,151.66% | May 20, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2018 |
| Roth Capital | Roth Capital | Strong Buy Initiates $193 | Strong Buy | Initiates | $193 | +25,917.03% | Jun 5, 2017 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $68,906 | Strong Buy | Initiates | $68,906 | +9,312,813.91% | Mar 6, 2013 |
Financial Forecast
Revenue This Year
10.85M
from 14.73M
Decreased by -26.33%
Revenue Next Year
12.73M
from 10.85M
Increased by 17.31%
EPS This Year
-1.42
from -138.65
EPS Next Year
-0.85
from -1.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 12.2M | 13.9M | 16.6M |
| Avg | 10.8M | 12.7M | 16.0M |
| Low | 9.7M | 11.8M | 15.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -17.4% | 27.8% | 30.7% |
| Avg | -26.3% | 17.3% | 25.8% |
| Low | -34.1% | 8.4% | 22.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.18 | -0.82 | -0.40 |
| Avg | -1.42 | -0.85 | -0.38 |
| Low | -2.60 | -0.89 | -0.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.